Onyx Pharmaceuticals (ONXX) CFO Announces Resignation
More News related to ONXX
- Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
- Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
- Onyx Pharma (ONXX) Active on Takeover Buzz
- Onyx Pharma (ONXX) volume & volatility Jump on sharp rally
- Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
More News related to Management Changes
- DaVita Prepares Florida Dialysis Patients for Hurricane Ike
- Red Bull Soapbox Teams Brave Torrential Downpour in the First Stop on a Four City Tour
- Red Bull Flugtag Brings Chicagoans Back to North Avenue Beach
- Progress Energy Storm-Related Outage Numbers Continue to Drop
- HHS Provides Prescription Drug and Durable Medical Equipment Assistance for Uninsured Louisiana Victims of Hurricane Gustav
Onyx Pharmaceuticals (Nasdaq: ONXX) today announced that its VP and CFO, Gregory Schafer, will resign from the company, effective December 15, 2008, or earlier if his successor is appointed prior to that time.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth in the United States and internationally.
Related Categories
Management ChangesStocks Mentioned
-0.55Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
